Cilengitide

Product overview
Catalog Number
PPH08-0331
Sequence
Cyclo(Arg-Gly-Asp-D-Phe-N-Me-Val)
Target
Selective Inhibitor of αvβ3 and αvβ5 with Possible Role in Tumor Therapy, The Arg-Gly-Asp (RGD) sequence is a highly conserved integrin recognition sequence within fibronectin.
Description
Cilengitide (EMD 121974) is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis (forming new blood vessels), and other aspects of tumor biology. Hence, it is under investigation for the treatment of glioblastoma, where it may act by inhibiting angiogenesis, and influencing tumor invasion and proliferation. Selective Inhibitor of avbeta3 and avbeta5 with Possible Role in Tumor Therapy. The Arg-Gly-Asp (RGD) sequence is a highly conserved integrin recognition sequence within fibronectin. TrifluoroAcetate Salt. C27H40N8O7. c(RGDf-NMeV)
Category
Catalog peptides, Biologically Active Peptides
Product Properties
Quantity

1mg, 5mg, 25mg
Storage

Shipped at 4°C. Store at -20°C for one year.
Purity

> 95%
Source

Synthetic
Forma appearance

Lyophilized powder
  • For research use only
  • Not for use in diagnostic procedures

€40,00 – €940,00 Tax excluded
Contact us to request price here
Register to buy peptides
Contact us